Randomized Trial for Pharmacogenomics-based Proton Pump Inhibitor Therapy in Children

Proton pump inhibitors are administered to children as off-label use in Japan. The purpose of this study is to evaluate the effects of CYP2C19 genotypes on pharmacokinetic /pharmacodynamic profiles of PPI in children. The results will provide the beneficial information for the individualized medicine of PPI in children.

Inclusion Criteria:

• Patients with gastroesophageal reflux
• The patient's parent or guardian gives written informed consent including pharmacogenomic analysis
• The patient is willing and able to give assent to participate.

Exclusion Criteria:

• Serious hepatic disease, pulmonary disease, renal disease and blood disorder
• Inadequate clinical conditions